Analysis of image data from the EuroNet PHL-C2 trial indicates a potential reduction in injected F-18 FDG activities in children: a proposal to update the EANM Paediatric Dosage Card.

"Declarations Ethics approval and consent to participateAll patients and/or their guardians provided written informed consent to participate in the EuroNet-PHL-C2 trial. This also included informed consent to provide anonymised data for scientific side projects like our analysis. The Clinical Board of the EuroNet-PHL-C2 study approved this project. An ethics approval was applied to the local ethics committee of the University of Leipzig (065/19-ek). No ethical concerns were expressed. All procedures in connection with this work were performed in accordance with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Competing interestsM Lassmann has received institutional grants by IPSEN Pharma, Nordic Nanovector and Novartis. No other potential conflicts of interest relevant to this article exist. Competing interests M Lassmann has received institutional grants by IPSEN Pharma, Nordic Nanovector and Novartis. No other potential conflicts of interest relevant to this article exist."

"Funding Open Access funding enabled and organized by Projekt DEAL. The work was in part funded by the Mitteldeutsche Kinderkrebsforschung – Stiftung für Forschung und Heilung, Leipzig, Germany."